Poa annua becomes the first weed to evolve resistance to indaziflam applied preemergence and early‐postemergence
Pest Management Science · 2026-01 · 82 (1) · 539-551
DOI: 10.1002/ps.70214 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pest Management Science, online erschienen am 08.09.2025. Verfasst von Joshua Wa Miranda und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Horticulture, Michigan State University, East Lansing, MI, USA. Hauptthemen laut MEDLINE: Herbicide Resistance, Plant Weeds, Herbicides, Triazines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ferrero Hazelnut Company, Oregon Hazelnut Commission.
Abstract (Originalsprache)
BACKGROUND Herbicide resistance evolution is a major challenge in agriculture. Poa annua L., a globally distributed and genetically diverse weed, has repeatedly evolved resistance to multiple herbicide sites of action due to its genetic plasticity and rapid life cycle. Indaziflam is widely used for P. annua control in several agroecosystems, with reports of postemergence resistance and a few confirmed cases of resistance to preemergence application. This study investigated suspected resistance to indaziflam in P. annua accessions from Oregon hazelnut orchards. RESULTS Whole‐plant dose–response assays confirmed indaziflam resistance in eight accessions ranging from 2.5‐ to 51‐fold relative to susceptible accessions, which had a lethal dose to 50% of the accession ( LD 50 ) of 1.0–3.4 g ha −1 . Resistance increased with plant developmental stage and was most pronounced when indaziflam was applied early‐postemergence, with some accessions surviving two‐ to four‐fold the labeled rate in tree nut orchards (50–95 g ha −1 ). Field experiments confirmed reduced efficacy of preemergence and early‐postemergence indaziflam treatments up to 195 g ha −1 . Indaziflam efficacy declined significantly across all accessions at air temperatures 9 °C:1 °C (day/night), with LD 50 values increasing up to eight‐fold across accessions compared to 25 °C:12 °C (day/night). Enzyme inhibitor seed‐based assays with cytochrome P450 and glutatione transferase inhibitors did not reverse resistance, suggesting resistance pathways other than enhanced metabolism may be involved. CONCLUSION This study provides the first confirmed cases of field‐evolved resistance to indaziflam applied both preemergence and early‐postemergence in P. annua . Resistance was most severe under cooler temperatures and postemergence use, highlighting environmental and developmental effects on indaziflam activity. © 2025 The Author(s). Pest Management Science published by John Wiley & Sons Ltd on behalf of Society of Chemical Industry.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Horticulture, Michigan State University, East Lansing, MI, USA.
- Department of Horticulture, Oregon State University, Corvallis, OR, USA.
- Department of Agricultural Biology, Colorado State University, Fort Collins, CO, USA.
ORCID-Profile: Joshua Wa Miranda, Todd A Gaines, Marcelo L Moretti
Förderung
- Ferrero Hazelnut Company
- Oregon Hazelnut Commission
Zitieren
APA
Miranda, J. W., Gaines, T. A., & Moretti, M. L. (2026). Poa annua becomes the first weed to evolve resistance to indaziflam applied preemergence and early‐postemergence. Pest Management Science, 82(1), 539-551. https://doi.org/10.1002/ps.70214
Vancouver
Miranda JW, Gaines TA, Moretti ML. Poa annua becomes the first weed to evolve resistance to indaziflam applied preemergence and early‐postemergence. Pest Management Science. 2026;82(1):539-551. doi:10.1002/ps.70214
BibTeX
@article{Miranda2026,
author = {Miranda, Joshua Wa and Gaines, Todd A and Moretti, Marcelo L},
title = {Poa annua becomes the first weed to evolve resistance to indaziflam applied preemergence and early‐postemergence},
journal = {Pest Management Science},
year = {2026},
volume = {82},
number = {1},
pages = {539--551},
doi = {10.1002/ps.70214}
}
EUVIMED